Understanding immunotherapy and its management

    DOI Logo 10.17352/2455-8591.000030

    Published On: January 12, 2021 | Pages: 001 - 007

    Author(s): Nadiminti Rajesh Kumar* and Sajid Alvi
    A few tumours are exceptionally stubborn to oral chemotherapy. The endurance of tumours in a few cases is helped by checkpoint immunomodulation to keep up the unevenness between resistant reconnaissance and disease cell division. Checkpoint counteracting agent inhibitors, for example, against PD-1/PD-L1, are another class of inhibitors that capacity has tumour stiflin ... CrossMark Publons Harvard Library HOLLIS Search IT Semantic Scholar Get Citation Base Search Scilit OAI-PMH ResearchGate Academic Microsoft GrowKudos
    Abstract View Full Article View


    Global Views

    Case Reports

    Peertechz Tweets

    Pinterest on IJICR